DESCRIPTION: Synthetic glucagon-like peptide-1 (GLP-1) mimetics are used to produce glycemic control either alone or in combination.

INDICATION(S): Treatment of Type II Diabetes (Diabetes Mellitus), lowering of Hemoglobin A1C, lowering of Fasting Blood Glucose

REASONS FOR Step Therapy: 
- ☒ Cost
- ☐ Potential for misuse
- ☐ Toxicity

CRITERIA for APPROVAL: The patient is an adult with type 2 diabetes mellitus AND has had a trial with ANY metformin OR inadequate control with ANY metformin prior to Byetta, Bydureon, Ozempic or Victoza (Preferred) and then has had a trial and failed Byetta, Bydureon, Ozempic or Victoza prior to Tanzeum, Trulicity or Adlyxin.

Metformin trial is not necessary for those with estimated glomerular filtration rate (eGFR) below 30 mL/minute/1.73 m²

REASON for DENIAL of BENEFIT: Patient does not meet above criteria.

BENEFIT APPROVAL: Approval for three years

POLICY HISTORY: Revised 6/18 for placement of Ozempic to Preferred status, addition of “or inadequate control” to Criterion for Approval section.
Revised 4/17 for potential of dual therapy w/ metformin
Revised 12/17 to add Ozempic and add indication for adults with DMII

References:
1. McEvoy G ed, Snow EK. AHFS Drug Information®, Bethesda, MD 2014
4. Ozempic (semaglutide) prescribing information. Novo Nordisk Plainsboro NJ December 2017